科美诊断(688468) - 2022 Q3 - 季度财报

Financial Performance - The company's operating revenue for Q3 2022 was ¥136,387,666.48, representing a year-over-year increase of 15.06%[2] - The net profit attributable to shareholders for Q3 2022 was ¥48,730,176.59, up 28.96% compared to the same period last year[2] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥39,021,176.07, reflecting a 31.81% increase year-over-year[2] - Basic earnings per share for Q3 2022 was ¥0.12, an increase of 33.33% from the previous year[3] - Total operating revenue for the first three quarters of 2022 reached ¥359,915,767.68, a slight increase of 1.3% compared to ¥355,463,272.78 in the same period of 2021[21] - Net profit for the third quarter of 2022 was ¥118,250,804.17, compared to ¥107,803,052.25 in the same quarter of 2021, representing an increase of 9.5%[23] - The total comprehensive income attributable to the parent company for Q3 2022 was ¥118,250,804.17, an increase from ¥107,803,052.25 in Q3 2021, representing a growth of approximately 13.4%[24] - Basic and diluted earnings per share for Q3 2022 were both ¥0.29, compared to ¥0.28 in Q3 2021, indicating a year-over-year increase of 3.6%[24] - The net profit for the first three quarters of 2022 was CNY 19,117,201.98, down 41.2% from CNY 32,622,695.40 in the previous year[30] - The company's total profit for the first three quarters was CNY 14,911,622.59, a decrease of 47.9% from CNY 28,651,680.77 in the same period of 2021[30] Research and Development - The total R&D investment for Q3 2022 was ¥23,890,313.89, which is 42.55% higher than the same period last year[3] - The R&D investment accounted for 17.52% of operating revenue, an increase of 3.38 percentage points year-over-year[3] - Research and development expenses for the third quarter of 2022 amounted to ¥51,337,884.31, an increase from ¥48,243,992.75 in the previous year, indicating a focus on innovation[22] - Research and development expenses increased to CNY 33,055,264.49, representing a rise of 26.6% compared to CNY 26,105,672.85 in the first three quarters of 2021[29] - The company obtained 14 authorized patents during the reporting period, including 1 domestic invention patent and 13 utility model patents[14] Cash Flow and Investments - The net cash flow from operating activities for the year-to-date period was ¥198,363,572.85, showing a 32.67% increase compared to the previous year[2] - The company's cash flow from operating activities remains strong, supporting ongoing investments in new product development and market expansion strategies[22] - Net cash flow from operating activities for the first three quarters of 2022 was ¥198,363,572.85, up from ¥149,520,066.42 in the same period of 2021, reflecting a growth of 32.6%[25] - Cash inflow from investment activities in the first three quarters of 2022 was ¥2,520,291,030.32, significantly higher than ¥1,496,493,979.06 in the same period of 2021, marking an increase of 68.4%[25] - The net cash flow from investment activities for the first three quarters of 2022 was -¥61,664,292.63, an improvement from -¥429,708,669.36 in the same period of 2021[25] - The company reported a net cash outflow from investing activities of CNY -33,466,720.20, an improvement from CNY -255,793,401.36 in the previous year[32] Assets and Liabilities - Total assets at the end of Q3 2022 were ¥1,518,753,584.76, a 6.14% increase from the end of the previous year[3] - Total assets as of the end of the third quarter of 2022 were ¥1,518,753,584.76, up from ¥1,430,906,695.48 at the end of the third quarter of 2021, marking a growth of 6.2%[19] - The company's equity attributable to shareholders reached ¥1,342,194,110.43, up from ¥1,278,672,724.44 in the previous year, showing an increase of 4.9%[19] - Total liabilities increased to ¥176,559,474.33 in the third quarter of 2022, compared to ¥152,233,971.04 in the same quarter of 2021, reflecting a rise of 16.0%[19] - The total liabilities as of September 30, 2022, were ¥28,525,537.88, a decrease from ¥47,669,901.28 as of December 31, 2021, indicating a reduction of approximately 40.2%[28] Shareholder Information - The company implemented a stock incentive plan, recognizing share-based payment expenses of ¥13,440,600, which impacted the net profit attributable to shareholders[4] - The company’s major shareholders include Shanghai Peixi Investment Management with 40,791,545 shares, representing a significant stake in the company[12] Inventory and Receivables - Accounts receivable decreased to ¥32,175,450.16 from ¥35,127,292.63, indicating a reduction of approximately 5.5%[17] - Inventory stood at ¥121,249,941.15, slightly down from ¥122,362,493.25 in the previous year[17] - The company’s fixed assets decreased to ¥113,671,670.15 from ¥125,905,381.60, reflecting a decline of about 9.7%[17] - The company’s long-term construction projects increased to ¥30,462,365.85 from ¥7,569,424.11, showing significant growth[17]